Aveo Oncology announces presentation of AV-203 Phase 1 results at 2014 American Society of Clinical Oncology Annual Meeting

02-06-2014 Business Wire HealthComments (0)

AVEO OncologyBiotechnologyPharmaceuticalUSA

Aveo Oncology (NASDAQ:AVEO) today announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3 (HER3) inhibitory antibody candidate. Among the results, the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy. The results were presented in a poster, entitled “First-in-human Phase 1 do

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top